Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,337
Out of 4,352 analysts
330
Total ratings
30.6%
Success rate
-16.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $17.33 | +182.75% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $7 → $13 | $14.07 | -7.60% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $7 → $9 | $2.17 | +314.75% | 23 | Apr 14, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $47 → $40 | $23.94 | +67.08% | 12 | Feb 13, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $8.07 | -13.26% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Maintained: Buy | $8 → $1 | $0.344 | +190.70% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Maintained: Buy | $64 → $46 | $14.97 | +207.28% | 29 | Dec 23, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $52 → $44 | $56.18 | -21.68% | 13 | Nov 11, 2025 | |
| TSHA Taysha Gene Therapies | Maintained: Buy | $7 → $12 | $5.87 | +104.43% | 26 | Oct 2, 2025 | |
| LCTX Lineage Cell Therapeutics | Reiterated: Buy | $5 | $1.33 | +275.94% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $3.46 | +73.41% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.87 | +365.12% | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $2.84 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.20 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $28.89 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.52 | n/a | 26 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $72 → $65 | $57.29 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $27 | $11.05 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $13.41 | n/a | 9 | Sep 26, 2023 |
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $17.33
Upside: +182.75%
Intellia Therapeutics
Apr 27, 2026
Maintained: Hold
Price Target: $7 → $13
Current: $14.07
Upside: -7.60%
Allogene Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $7 → $9
Current: $2.17
Upside: +314.75%
Ultragenyx Pharmaceutical
Feb 13, 2026
Maintained: Buy
Price Target: $47 → $40
Current: $23.94
Upside: +67.08%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $8.07
Upside: -13.26%
Mereo BioPharma Group
Dec 29, 2025
Maintained: Buy
Price Target: $8 → $1
Current: $0.344
Upside: +190.70%
Vor Biopharma
Dec 23, 2025
Maintained: Buy
Price Target: $64 → $46
Current: $14.97
Upside: +207.28%
CRISPR Therapeutics AG
Nov 11, 2025
Maintained: Hold
Price Target: $52 → $44
Current: $56.18
Upside: -21.68%
Taysha Gene Therapies
Oct 2, 2025
Maintained: Buy
Price Target: $7 → $12
Current: $5.87
Upside: +104.43%
Lineage Cell Therapeutics
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.33
Upside: +275.94%
Aug 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $3.46
Upside: +73.41%
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $3.87
Upside: +365.12%
May 14, 2025
Maintained: Hold
Price Target: $5 → $4
Current: $2.84
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $12.20
Upside: n/a
Nov 6, 2024
Maintained: Buy
Price Target: $84
Current: $28.89
Upside: n/a
Nov 5, 2024
Maintained: Buy
Price Target: $10
Current: $3.52
Upside: n/a
Oct 30, 2024
Maintained: Hold
Price Target: $72 → $65
Current: $57.29
Upside: n/a
Nov 16, 2023
Maintained: Hold
Price Target: $27
Current: $11.05
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $13.41
Upside: n/a